| Symbol | KROS |
|---|---|
| Name | KEROS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 99 HAYDEN AVENUE,SUITE 120, BUILDING E, LEXINGTON, Massachusetts, 02421, United States |
| Telephone | +1 617 314-6297 |
| Fax | — |
| — | |
| Website | https://www.kerostx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001664710 |
| Description | Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The companys protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Keros Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062702 <b>Size:</b> 10 KB
Read more(10% Negative) KEROS THERAPEUTICS, INC. (KROS) Reports Q2 2026 Financial Results
Read moreNew Form ARS - Keros Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001104659-26-046817 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Keros Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001104659-26-046801 <b>Size:</b> 452 KB
Read moreBIENAIME JEAN JACQUES 🟢 acquired 1.0K shares of Keros Therapeutics, Inc. (KROS) at $11.70 Transaction Date: Apr 15, 2026 | Filing ID: 000005
Read moreNew Form SCHEDULE 13G - Keros Therapeutics, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0002012383-26-001069 <b>Size:</b> 10 KB
Read moreSeehra Jasbir 🟡 adjusted position in 0 shares (1 derivative) of Keros Therapeutics, Inc. (KROS) at $0.30 Transaction Date: Apr 02, 2026 | Filing ID: 000010
Read more📋 OrbiMed Genesis Master Fund, LP (Shareholder) plans to sell 45K shares of Keros Therapeutics, Inc. (at $11.04 each, total $497K) Filed: Mar 31, 2026 | ID: 000370
Read moreNew Form SCHEDULE 13G/A - Keros Therapeutics, Inc. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0000102909-26-001617 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05927012 | A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Do… | Phase2 | Iron Deficiency Anemia | Withdrawn | 2023-11-30 | 2026-01-04 | ClinicalTrials.gov |
| NCT05975905 | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With B… | Phase2 | Pulmonary Arterial Hypertension | Completed | 2023-10-17 | 2025-03-11 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KER-047 | Other | Phase PHASE2 | Iron Deficiency Anemia | WITHDRAWN | NCT05927012 |
| Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose C KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose B KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose A KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose C KER-012 | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose B KER-012 | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose A KER-012 | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| KER-047 | DRUG | Phase PHASE2 | Iron Deficiency Anemia | WITHDRAWN | NCT05927012 |